Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. (2023)

First Author: González-Cordón A
Attributed to:  Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkad247

PubMed Identifier: 37539492

Publication URI: http://europepmc.org/abstract/MED/37539492

Type: Journal Article/Review

Volume: 78

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 9

ISSN: 0305-7453